Improving Therapeutic Learning in Depression: Proof of Concept



Status:Completed
Conditions:Depression, Depression, Major Depression Disorder (MDD)
Therapuetic Areas:Psychiatry / Psychology, Pulmonary / Respiratory Diseases
Healthy:No
Age Range:18 - 65
Updated:9/21/2018
Start Date:September 16, 2014
End Date:May 2017

Use our guide to learn which trials are right for you!

Despite advances in both pharmacotherapy and psychotherapy for major depression, non-response
and partial-response remain relatively common outcomes, motivating the search for new
treatments. This study is concerned with the development of one such novel treatment, the
augmentation of exposure-based cognitive-behavior therapy (CBT) with d-cycloserine (DCS).

Investigators will study the efficacy of DCS for augmenting therapeutic learning relevant for
the treatment of depression (i.e., outside the extinction learning where DCS has been shown
to have success). Specifically, the study investigates the role of DCS in enhancing
declarative memory in depressed individuals, as evaluated by standardized tests and the
retention of cognitive therapy session material. Investigators will also study an active
comparison agent, modafinil, which appears to offer cognitive enhancing effects among both
sleep-deprived and non-sleep-deprived individuals, but also appears to have drug-state (e.g.,
mood and side) effects that are not characteristic of DCS augmentation. Therefore,
drug-context effects may affect memory retention over time. Hence, the study will evaluate
memory enhancement effects both during the period of drug action as well as one week later
when no drug is taken. Overall, investigators will examine cognitive function and memory
performance over 4 study sessions in 96 men and women with major depression, who, in a
double-blind fashion, will be randomly assigned to either: (1) 250mg DCS, (2) 100mg
modafinil, or (3) placebo administered on Study Weeks 2 and 3. The memory tests include both
items unique to a given study week and memory tasks that are repeated over time that allow
assessment of memory and retention effects across one-week periods.

Inclusion Criteria:

- Must have a DSM diagnosis of major depression as determined by structured diagnostic
interview

- Must be free of psychotropic medications other than serotonin selective reuptake
inhibitors (SSRIs) for at least 2 weeks

- No current suicidal ideation

- Able to speak and understand English

- Must be between the ages of 18 and 65, inclusive

- Must be a male, or a female who is not of childbearing potential (i.e., surgically
sterile, postmenopausal for at least 1 year) or who is non-pregnant, non-lactating and
using a medically accepted method of contraception. Acceptable methods of
contraception include condoms (male or female) with or without a spermicidal agent,
diaphragm or cervical cap with spermicide, medically prescribed IUD, hormonal
contraceptives. A woman of childbearing potential who is not currently sexually active
must agree to use a medically accepted method of contraception should she become
sexually active while participating in the trial

Exclusion Criteria:

- A DSM diagnosis of dementia, neurodegenerative disease, or other organic mental
disorder; substance use disorder other than nicotine or caffeine in the last 3 months;
bulimia or anorexia within the last 3 months; lifetime history of psychotic disorder
or, bipolar disorder, or developmental disorder;

- A diagnosis of organic brain syndrome, mental retardation, or other cognitive
dysfunction that could interfere with a participants capacity to participate in CBT or
to complete safety and efficacy assessments

- A history of seizures (apart from childhood febrile seizures) or head trauma causing
ongoing cognitive impairment

- An uncontrolled, unstable clinically significant medical condition (e.g., renal,
endocrine, hepatic, respiratory, cardiovascular, hematologic, immunologic or
cerebrovascular disease, or malignancy, or poorly controlled hypertension (>
150/90mmHg) that may interfere with the interpretation of safety and efficacy
evaluations in the opinion of the study physician or investigator

- Medical illness including hypertension, cardiac disease, liver disease, pulmonary
diseases, central nervous system disease, and epilepsy;

- Recent (1 year) suicidal attempts or current suicidal ideation

- For women, currently pregnant, plans to be pregnant in the next 2 months, or currently
breastfeeding

- Treatment with phenytoin, isoniazid, or propranolol or known sensitivity to modafinil
or cycloserine

- A history of head trauma causing loss of consciousness, seizure or ongoing cognitive
impairment

- Use of psychotropic medication (including stimulants) other than SSRIs

- Current daily use of alcohol or regular binge alcohol use as determined on the medical
screen

- Insufficient command of the English language (i.e., cannot carry on a conversation
with an interviewer in the English language or read associated text)

- Receipt of CBT in the previous five years
We found this trial at
1
site
One Silber Way
Boston, Massachusetts 02215
(617) 353-2000
Principal Investigator: Michael W. Otto, Ph.D.
Phone: 617-353-9610
Boston University Boston University is no small operation . With over 33,000 undergraduate and graduate...
?
mi
from
Boston, MA
Click here to add this to my saved trials